Pharmasset, Inc. Company Profile

News Articles [ 17 Associated News Articles listed on BioPortfolio]

J&J Joins Pharmasset for Hepatitis Study

Princeton, NJ-based Pharmasset (NASDAQ: VRUS) is teaming up with Johnson & Johnson (NYSE: JNJ) unit Tibotec to study a drug cocktail for the treatment of hepatitis C virus (HCV), according to a...

PropThink: PropThink: Gilead and the Pharmasset Deal: Do the Ends Justify the Means?

By David Sobek In November of 2011, Gilead (http://www.gilead.com/)(NASDAQ:GILD) announced that it reached an agreement (http://www.gilead.com/pr_1632335)to purchase Pharmasset for $11 billion, an...

Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble

Since Gilead’s $11 billion buyout of Pharmasset in late 2011, large- and mid-cap biotech share prices have been on the rise. Plus news on recent financing activity by Ophthotech, Effector Therapeuti...

Gilead's 3Q Profit Slips on Acquisition Costs

From Associated Press (October 23, 2012) FOSTER CITY, Calif. -- HIV drug maker Gilead Sciences Inc. said Tuesday that its third-quarter profit slipped on costs related to its purchase of hepatitis C...

Gilead's 3Q profit slips on acquisition costs

HIV drug maker Gilead Sciences Inc. said Tuesday that its third-quarter profit slipped on costs related to its purchase of hepatitis C drug developer Pharmasset Inc. But results still topped expectat...

Former Bristol-Myers Exec Pleads Guilty To Insider Trading

A former Bristol-Myers Squibb executive pleaded guilty to insider trading for buying stock options in three drugmakers that were targeted for acquisition, which yielded more than $311...

Gilead Sciences profit slips on acquisition costs

HIV drug maker Gilead Sciences Inc. said Thursday its second-quarter profit slipped 4 percent on costs related to its purchase of hepatitis C drug developer Pharmasset Inc.The company said revenue in...

Gilead Sciences : Company profile

Return to top bigbiotech list Summary Website: Gilead Headquarters: California, USA Ticker Symbol: GILD (Nasdaq StockExchange) GIS (Frankfurt Stock Exchange) SEC Link: Gilead Subsidiaries: ArrestoÂ...

Drugs and Medications [0 Results]

None

PubMed Articles [ 10 Associated PubMed Articles listed on BioPortfolio]

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease. The HCV NS5B polymerase has been demonstrated to be a viable target for the devel...

Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase.

Nucleotide prodrugs for HCV therapy.

HCV infection is a significant worldwide health problem and is a major cause of hepatocellular carcinoma. The current standard of care, interferon and ribavirin, is only effective against a proportion...

Rapid differentiation of nucleotide phosphoramidate diastereomers by electrospray ionization tandem mass spectrometry.

Nucleotide phosphoramidates are prodrugs which effectively deliver the active nucleotide to target tissues. It was shown that the individual phosphoramidate diastereomers have different antiviral acti...

The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.

A recent study indicated that addition of the hepatitis B e antigen (HBeAg) precore (PC) or basal core promoter (BCP) mutations to wild-type HBV offset the reduced replication of the HBV polymerase rt...

Clinical Trials [0 Results]

None

Companies [ 1 Associated Companies listed on BioPortfolio]

Pharmasset, Inc.

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...